IRCT20201227049854N1CompletedPhase 3
Evaluation of the effect of Silymarin on hepatotoxicity induced by Remdesivir in patients with COVID-19 admitted to Shahrekord hospitals
Shahre-kord University of Medical Sciences0 sites70 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with positive covid19 PCR test who have been treated with Remdesivir
- •Patient with lung infiltration
- •Absence of underlying liver disease
- •Liver enzymes less than 5 times normal
Exclusion Criteria
- •Increased liver enzymes more than 5 times normal
- •Patient dissatisfaction
- •Pregnant or lactating patients
- •Patients with glomerular filtration less than 50 mg / min
Investigators
Similar Trials
Completed
Phase 2
Effect of Silymarin on Non Alcoholic Steatohepatitison alcocholic steatohepatitis.Fatty (change of) liver, not elsewhere classifiedIRCT138805172308N1Mazandaran University of Medical Sciences and Health Services50
Completed
Not Applicable
Protective effects of silymarin on cardiac and hepatic side effects of chemotherapy drugsIRCT2017071935175N1Vice chancellor for research, Isfahan University of Medical Sciences40
Not yet recruiting
Phase 3
Effect of silymarin in the treatment of patients with depressioIRCT20160804029191N4Mashhad University of Medical Sciences80
Recruiting
Phase 3
Investigating the effects of Silymarin in the treatment of neonatal jaundiceIRCT20211122053144N1Mashhad University of Medical Sciences60
Completed
Phase 3
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64